Imran Eba

Alpheus Medical, Inc, is a privately held company based in Oakdale, Minnesota, developing a novel sonodynamic therapy platform targeting solid body cancers. The company’s lead product utilizes a novel, non-invasive drug device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM). Alpheus Medical’s work has been developed in conjunction with some of the most accomplished names worldwide in neuro-oncology, and with support from the American Cancer Society and National Brain Tumor Society.

Neuspera Medical, Inc. is committed to developing implantable medical device technology that will improve the lives of patients battling chronic illness. With the first intended indication for use as Urinary Urgency Incontinence (UUI), the platform technology is ultimately designed to deliver targeted bioelectronic medicine for a variety of conditions. Neuspera’s minimally-invasive implants with external wearable transmitters offer the possibility for therapies to reach deeper, harder to access anatomical locations in the body.

Axon Therapies is addressing a root cause of heart failure with their frontline therapy by selectively ablating the neural pathway carrying information from the chronically hyperactive sympathetic nervous system (SNS) in order to restore volume balance, stop disease progression and improve symptoms

SetPoint Medical is developing novel bioelectronic medicine therapies to treat those who suffer from autoimmune diseases such as rheumatoid arthritis, Crohn's Disease and multiple sclerosis. The company has developed a proprietary and innovative bioelectronic medicine platform consisting of a micro-regulator programmed via a unique prescription pad based interface. This novel therapy has the potential to provide patients and healthcare providers with a safe and efficacious alternative to drugs, while costing payers significantly less than biologic therapies.

Brooke Charter Schools is a network of high-performing public charter schools in Boston. Our mission is to provide an academically rigorous public education that will ensure our students are prepared to attend and succeed in college and beyond. Named after the late Senator Edward W. Brooke, the first African-American popularly elected to the U.S. Senate, Brooke Charter Schools has achieved exceptional results for historically underserved students through a relentless focus on excellent teaching.

Mobia Medical, Inc. (formerly MicroTransponder, Inc.) is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Companys breakthrough Vivistim® Paired VNS™ System is the first FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Vivistim Paired VNS Therapy combines targeted vagus nerve stimulation with functional movement to promote neuroplasticity and drive meaningful improvements in motor function. For more information, visit Vivistim.com and review safety information at Vivistim.com/safety.

Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. The nine-month program employs an objectives-based mentoring process to enhance the performance of technical founders who learn from the insights of experienced entrepreneurs, with the goal of maximizing equity-value creation. Founded by Professor Ajay Agrawal in 2012 at the University of Toronto’s Rotman School of Management, the program has expanded and now has 11 sites across six countries: Toronto, Vancouver, Calgary, Montreal, Halifax, Paris, Madison, Seattle, Estonia, Berlin, and Melbourne. The program combines 5 elements to help companies transition from science projects to scalable and financeable companies: - An emphasis on objective-setting, helping companies focus on what’s most important to their business - Focused mentorship from experienced entrepreneurs who have founded, led, and sold significant tech companies - Technical advice from world-leading scientists, engineers, and economists - Hands-on support from top business students, who embed within the company to provide business support - Opportunities to raise capital, including angels and VCs from Europe and North America The successful commercialization of cutting-edge science and technology achieved through the program has led to the creation of over CAD $35 billion in equity value.

Alpheus Medical, Inc, is a privately held company based in Oakdale, Minnesota, developing a novel sonodynamic therapy platform targeting solid body cancers. The company’s lead product utilizes a novel, non-invasive drug device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM). Alpheus Medical’s work has been developed in conjunction with some of the most accomplished names worldwide in neuro-oncology, and with support from the American Cancer Society and National Brain Tumor Society.

Neuspera Medical, Inc. is committed to developing implantable medical device technology that will improve the lives of patients battling chronic illness. With the first intended indication for use as Urinary Urgency Incontinence (UUI), the platform technology is ultimately designed to deliver targeted bioelectronic medicine for a variety of conditions. Neuspera’s minimally-invasive implants with external wearable transmitters offer the possibility for therapies to reach deeper, harder to access anatomical locations in the body.